Ultralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies.
Wang D, Porter CE, Lim B, Rosewell Shaw A, Robertson CS, Woods ML, Xu Y, Biegert GGW, Morita D, Wang T, Grilley BJ, Heslop H, Brenner MK, Suzuki M.
Wang D, et al. Among authors: woods ml.
Sci Adv. 2023 Mar 29;9(13):eade6790. doi: 10.1126/sciadv.ade6790. Epub 2023 Mar 29.
Sci Adv. 2023.
PMID: 36989357
Free PMC article.